Taisho Pharmaceutical Co., Ltd.

Mitsubishi Electric Corporation

Yohei Matsuda

Seiji Masuda

Norikazu Otake

Yuko Yamauchi

Takashi Hashihayata

Hiroshi Ohta

Tsuyoshi Shibata

Toshio Nakamura

Kazunari Sakagami

Mao Kawamura

Akito Yasuhara

Yohei Kobashi

Kanako Yamamoto

Daisuke Matsuda

Minoru Moriya

Hideaki Tabuse

Rie Shimono

Tomokazu Tamaoki

Kazuhide Konishi

Kumiko Okada

Hiroshi Kawamoto

In order to suppress oscillation and malfunction of a switching element in a power converter, the power converter includes a switching element; and an oscillation suppression circuit having a stub which is electrically connected to a terminal of the switching element. A signal of the oscillation frequency is suppressed based on a length of the stub relative to a wavelength of the oscillation frequency. When an incident wave reflects from the open end of the stub, the reflected wave is out of phase with the incident wave, and the incident wave and the reflected wave cancel each other.

Power converter

Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on. 

Prodrug amino acid derivative

Prodrug of amino acid derivative

A novel process for producing optically active 2-(2-fluorobiphenyl-4-yl)propanoic acid is disclosed. This production process is characterized in that a compound of formula [1] is reacted with magnesium and so forth to prepare an organometallic reagent, which is reacted with a compound of formula [2] in the presence of a catalytic amount of a nickel compound and a catalytic amount of an optically active compound of formula [3] to obtain a compound represented by formula [4] which is subsequently converted to a compound represented by formula [5] or a pharmaceutically acceptable salt thereof. 

Method for producing optically active 2-(2-fluorobiphenyl-4-yl) propanoic acid

An isolated DC/DC converter () includes a full-bridge type switching circuit. A primary winding of a transformer () and a resonance reactor () are connected in series to each other. Another end of each of the primary winding and the resonance reactor () is connected to one of middle points between switching elements. First and second surge suppression diodes (Dand D) are provided to a node between the resonance reactor () and the primary winding of the transformer () and between a positive side and a negative side of a capacitor (). This configuration suppresses a surge voltage applied to the transformer by releasing surge energy of the resonance reactor () caused by a recovery of rectifying diodes (Dto D) on a secondary side of the transformer () via the surge suppression diodes (Dand D).

In-vehicle charger and surge-suppression method in in-vehicle charger

Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like. 

Ethinyl-pyrazole derivative

Growing community of inventors

Tokyo, Japan

Yohei Matsuda